- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Article
Revance Positioned to Launch RHA Dermal Fillers in U.S.
Author(s):
Revance announces that it will begin introducing its prestige aesthetics portfolio with the RHA collection of dermal fillers this September.
Revance Therapeutics recently announced it will begin introducing its prestige aesthetics portfolio, with the RHA collection of dermal fillers, in the United States this September. The portfolio also includes resilient hyaluronic acid, and the HintMD financial technology (fintech) platform.
The RHA collection includes the first and only FDA-approved dermal fillers for correction of dynamic facial wrinkles and folds, according to the company. These HA fillers are designed with a crosslinking method that preserves the hyaluronic acid network to mimic natural HA found in the skin.
Related: Revance to Introduce TEOXANE RHA Fillers in the U.S.
The company says it is ready for the product launch now that they have onboarded and trained a 100+ field force team.
They plan to use the same infrastructure for the launch of DaxibotulinumtoxinA (DAXI) injection for the treatment of glabellar lines upon its expected FDA approval later this year.
“Revance is positioned to re-energize the aesthetics industry with the creation of a prestige category of innovative products and services and elevated customer and patient experiences available through select practices. Our commercial team, comprised of industry experts with decades of aesthetics and commercial experience, is now trained and in position to execute Revance’s first commercial launch,” says Dustin S. Sjuts, Revance chief commercial officer, in the press release. “We are delighted to be entering the market with the RHA® Collection, the latest innovation in HA technology, and an integrated fintech platform designed to transform existing payment processing ecosystems and improve both aesthetics practice economics and patient experiences. We plan to follow with our lead investigational candidate DaxibotulinumtoxinA for Injection after its anticipated approval, which is just around the corner.”
Related:
Revance Reports Positive Results in Two Phase 2a Studies of DAXI
